Cellular diagramFor the past nearly three decades, Dr. Srivastava’s research has been focused on the following two parvoviruses, the non-pathogenic adeno-associated virus (AAV), and a common human pathogen, the parvovirus B19, and the development of recombinant parvovirus vectors for human gene therapy.

More recently, the next generation of recombinant AAV vectors has been developed that transduce cells and tissues more efficiently at lower vector doses. The current emphasis is on developing recombinant parvovirus vectors for gene therapy for genetic diseases such a B-thalassemia and sickle cell disease, and malignant disorders such as erythroleukemia, hepatoblastoma and hepatocellular carcinoma.